Covid 19 Research using Clinical Trials (Home Page)
Report for D001997: Bronchopulmonary Dysplasia NIH
(Synonyms: Bronchopulmonary Dysplasia)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug837 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 1.00 |
| drug125 | Biosensors Wiki | 1.00 |
Correlated MeSH Terms (12)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006470 | Hemorrhage NIH | 1.00 |
| D006929 | Hyperaldosteronism NIH | 1.00 |
| D014552 | Urinary Tract Infections NIH | 1.00 |
| D000309 | Adrenal Insufficiency NIH | 1.00 |
| D054559 | Hyperphosphatemia NIH | 1.00 |
| D007008 | Hypokalemia NIH | 1.00 |
| D008595 | Menorrhagia NIH | 1.00 |
| D006973 | Hypertension NIH | 0.45 |
| D003141 | Communicable Diseases NIH | 0.12 |
| D007239 | Infection NIH | 0.08 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
| D018352 | Coronavirus Infections NIH | 0.06 |
Correlated HPO Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000132 | Menorrhagia HPO | 1.00 |
| HP:0002900 | Hypokalemia HPO | 1.00 |
| HP:0000859 | Hyperaldosteronism HPO | 1.00 |
| HP:0000846 | Adrenal insufficiency HPO | 1.00 |
| HP:0000822 | Hypertension HPO | 0.71 |
There is one clinical trial.
Clinical Trials
1 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
NCT04278404 Coronavirus Infection (COVID-19) Pulmonary Arterial Hypertension Urinary Tract Infections in Children Hypertension Pain Hyperphosphatemia Primary Hyperaldosteronism Edema Hypokalemia Heart Failure Hemophilia Prior to Tooth Extraction Menorrhagia Insomnia Pneumonia Skin Infection Arrythmia Asthma in Children Bronchopulmonary Dysplasia Adrenal Insufficiency Hypertension, Resistant to Conventional Therapy Fibrinolysis; Hemorrhage Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Menorrhagia Hypertension Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Hemorrhage
HPO:Adrenal insufficiency Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism
Primary Outcomes
Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Elimination rate constant (ke) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Half-life (t1/2) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Absorption rate constant (ka) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: AUC (area under the curve) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Maximum concentration (Cmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.
Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.